PSTV: CNS Delivery And New CPT Codes Will Drive Future Upside

Analysts have adjusted their view on Plus Therapeutics, cutting the average price target by $25.50 while updating their models for fair value, discount rate, profit margin and future P/E to reflect a mix of rating changes and new coverage.

Analyst Commentary

Recent Street research on Plus Therapeutics reflects a mix of optimism about long term potential and caution around execution and valuation, with one firm initiating coverage positively and others resetting expectations through a downgrade and a lower price target.

Bullish Takeaways

Bullish analysts initiating coverage with a positive stance appear to see room for value creation if the company executes on its clinical and operational plans, especially relative to their updated fair value work.
The supportive initiation suggests confidence that the current valuation already reflects some of the known risks, leaving upside if milestones are met in a reasonable time frame.
Positive commentary in the recent initiation implies that certain growth drivers, such as pipeline progress or potential market opportunities, are viewed as meaningful if the company can deliver against expectations.
Bullish analysts framing the story positively may be comfortable with near term volatility as long as the long run risk or reward profile, including future P/E assumptions, stays intact.

Bearish Takeaways

Bearish analysts cutting the price target by $25.50 signal that previous assumptions on valuation, including fair value and discount rate inputs, required a reset given current information.
The recent downgrade highlights concern that execution risks or timing of key milestones could limit how quickly the company can justify prior valuation levels.
Lowered models on profit margin and future P/E suggest a more conservative stance on how efficiently Plus Therapeutics might scale and how the market could value that growth.
The combination of downgrade and target cut points to a more cautious view on risk or reward, with some analysts preferring clearer evidence of operational progress before assigning higher multiples.

What's in the News

Initiation of manufacturing and technology transfer with SpectronRx under an existing Master Services Agreement, establishing a second GMP site alongside Radiomedix for late stage clinical production of Rhenium-186 and REYOBIQ and expanding the multi partner radiopharmaceutical supply chain with Telix Pharmaceuticals supplying Rhenium-186 (Product related announcement).
American Medical Association approval of a new Proprietary Laboratory Analyses CPT code 0640U for the CNSide CSF Tumor Cell Enumeration test, creating a dedicated billing identifier to support payer reimbursement, clinician adoption and tracking of U.S. commercial use for the CNS metastases diagnostic platform (Product related announcement).
American Medical Association CPT Editorial Panel approval of a new Category III CPT code to track convection enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer, supporting standardized utilization tracking as part of the path toward commercialization and reimbursement (Product related announcement).
Board approval of a 1 for 25 reverse stock split of common shares, effective April 2, 2026, with the aim of keeping the Nasdaq Capital Market listing by supporting compliance with the minimum $1.00 bid price requirement and subsequent confirmation from Nasdaq that Plus Therapeutics has regained compliance after the stock traded at or above $1.00 for 10 consecutive business days from April 6 to April 17, 2026 (Company filings and Nasdaq notification).
Filing of the 10 K for the period ending December 31, 2025, in which auditor CBIZ CPAs P.C. issued an unqualified opinion that included substantial doubt about the company's ability to continue as a going concern (10 K filing).

Valuation Changes

Fair Value, modeled at $5.30 previously, is now set at $38.00, representing a very large upward reset in the analysts' fair value estimate.
Discount Rate, adjusted from 7.10% to 7.17%, has risen slightly, indicating a modestly higher required return in the models.
Revenue Growth, kept effectively unchanged at a very large triple digit level, reflects that analysts are holding their prior growth assumption steady in the updated work.
Profit Margin, refined from 12.51% to 12.77%, has edged higher, suggesting a slightly more optimistic view of future profitability.
Future P/E, moved from 229.03x to 61.39x, has fallen significantly, pointing to a much lower multiple being used in forward valuation assumptions.

9 views

Key Takeaways

Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.
Advancements and strategic partnerships indicate significant market opportunities, enhancing revenue potential and profit margins through reduced costs and expanded markets.
High clinical trial investments, reliance on grant funding, and regulatory challenges could stress Plus Therapeutics' financial stability and delay revenue growth.

Catalysts

About Plus Therapeutics

A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.What are the underlying business or industry changes driving this perspective?

The recent completion of a $15 million equity financing, alongside additional grant proceeds, has strengthened Plus Therapeutics' balance sheet, ensuring adequate funding through key milestones, enhancing the financial position and potentially leading to future earnings growth.
Recruitment of seasoned leadership with extensive experience in oncology and diagnostics can drive efficient execution of clinical development, which could positively impact revenue if new treatments are successfully brought to market.
Advancement of REYOBIQ’s clinical trials, including FDA orphan drug designation and Fast Track status for LM related to lung and breast cancer, suggests an expedited path to approval, potentially impacting future revenue streams.
The anticipated market entry of CNSide, a cancer testing platform, presents a significant market opportunity, with a potential increase in total addressable market by 2 to 4 times, which could boost future revenue and profit margins.
Strategic partnerships for drug production and supply chain optimization aim to meet future commercial demand for REYOBIQ, minimizing production costs and potentially improving net margins.

Plus Therapeutics Earnings and Revenue Growth

Plus Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Plus Therapeutics's revenue will grow by 109.2% annually over the next 3 years.
Analysts are not forecasting that Plus Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Plus Therapeutics's profit margin will increase from -429.4% to the average US Biotechs industry of 12.8% in 3 years.
If Plus Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $6.1 million (and earnings per share of $0.73) by about May 2029, up from -$22.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 64.5x on those 2029 earnings, up from -1.9x today. This future PE is greater than the current PE for the US Biotechs industry at 16.3x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.17%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Plus Therapeutics continues to invest substantially in clinical trials, which has led to increased spending and an operating loss of $14.7 million for 2024. This trend, if continued, could negatively impact net margins and financial stability.
The company's reliance on grant revenue for funding its operations, such as the CPRIT, NIH, and Department of Defense grants, introduces a risk if future grant funding does not meet expectations, potentially impacting earnings and cash flow.
There are risks associated with the clinical development pathway and regulatory approval for REYOBIQ, given the complexities of aligning with the FDA for trial design, endpoints, and patient subtypes, which could delay commercialization and revenue generation.
The competitive landscape and evolving nature of CNS cancer treatment diagnostics could pose challenges for CNSide's market penetration, affecting projected revenue from its diagnostic platform.
To expand diagnostic operations, sales, and market access broadly across the U.S., substantial investments in the sales force and operational infrastructure are required, which could strain financial resources and affect future profitability and cash position.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $38.0 for Plus Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $65.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $47.7 million, earnings will come to $6.1 million, and it would be trading on a PE ratio of 64.5x, assuming you use a discount rate of 7.2%.
Given the current share price of $6.09, the analyst price target of $38.0 is 84.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Plus Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress